skip to content

Axis 1/Subject 3 - International Institutions and Political Initiatives: What impact on accessing quality MEGs?

Presentations:
 
 .

Influence of the Global Fund in countries' procurement policies

Speaker

Joëlle DAVIAUD, pharmacist, Quality Assurance Manager, Global Fund (Geneva).

General scheme of the Presentation

Presentation of the Global Fund Quality Assurance policy for pharmaceutical products, including registration and pre qualification activities and quality control.

Global Fund Website
Essential questions on which the presentation is based

What are the influence and impact of applying the Global Fund Quality Assurance policy to the medicines market?
What are the perspectives for extending this policy to other donors, other molecules (the « non-ATM » types)?

 

Mechanisms which could be put in place to improve accessibility to quality ACTs: the AMFm

Speaker

Jan VAN ERPS, public health doctor, the Roll Back Malaria Secretariat (Geneva), AMFm Project manager.

General scheme of the Presentation
  • Presentation of the AMFm project, perspectives and most recent advances.
  • « The Affordable Medicines Facility - malaria (AMFm) » is an innovatory financing mechanism whose purpose is to improve access to the most effective treatments for malaria, therapeutic combinations based on Artemisinin (ACT).
  • The project is managed by the Global Fund with financial support from UNITAID, DFID and other donors. Roll Back Malaria (RBM) is an important partner involved in this initiative.
  • The principle is to reduce the sale price of ACT in the public and private sectors and for non profit organisation purchasers. The Global Fund negotiates a more advantageous purchase price for ACT, financing a proportion of the price directly with the producer in the name of the donor (joint payment system).
  • In practice this leads to the purchaser paying no more than 0.05 USD per ACT treatment. The patient can then obtain an ACT treatment for a price in the range 0.2 to 0.5 USD instead of the 6 to 7 USD previously (average of the current cost price)
Essential questions on which the presentation is based
  • Results of the project?
  • Could this type of mechanism be applied to other molecules?
 

Quality from the regulatory and institutional point of view: the role played by Belgium in exporting (« Because Health » Network)

Speaker

Raffaella RAVINETTO, pharmacist, Director of the Unit for Clinical Trials at the Institute of Tropical Medicine in Antwerp (Belgium), member of the working group on medicines in the Because Health Network.

General scheme of the Presentation
  • Presentation of the goals and results of the working group on medicines (BH-WGM) .
  • Presentation of the « Quality Charter » launched in 2007, information on the signatory organisations and estimates of the impact of this initiative on improvement of regulation over the international pharmaceutical market.
  • The Because Health working group on medicines regroups a number of organisations and individuals concerned with problems of accessibility to quality medicines in low and middle income countries. The main members of the Group are: Coopération Technique Belge (CTB), Memisa, Africa Europe Faith and Justice Network (AEFJN), MSF Belgique, the Damien Foundation at the Antwerp Institute of Tropical Medicine and AEDES.
  • The aim of the working group is to influence policy in Belgium both at government and organisational levels.
  • Recent discussions have concerned the quality of medicines from two perspectives: (i) a regulatory perspective with the accent on export regulations on exports from European countries and their consequences in terms of access to quality medicines in PEDs; (ii) an institutional perspective with the emphasis on improving the organisation of quality assurance (policy and system) by organisations and institutions involved in the procurement and distribution of medicines and other medical products intended for (consumption in) low and middle income countries.
Essential questions on which the presentation is based
  • What actions should be undertaken by countries in the Northern hemisphere in terms of exporting MEGs to low and middle income countries?
  • What lessons can be drawn from the experience of the Because Health network?
 

« Access to Medicines Index »: a method for classifying pharmaceutical companies in terms of access to medicines in low and middle income countries

Speaker

Wim LEEREVELD, Director of "Access to Medicine Index".

General scheme of the Presentation

Presentation of the system and classification methods for industrial pharmaceutical companies in terms of criteria of accessibility to essential medicines which is the basis of « ATM-Index » policy.

Essential questions on which the presentation is based
  • What are the comparative and communication classificatory principles at the base of the ATM-Index system?
  • What methodology is applied in the current classification?
  • What is the current coverage of the system, in particular with respect to producers of generic medicines, and more particularly with respect to products destined for low and middle income countries?
  • What is the current role of quality aspects in the classification and how could it be integrated / developed?